This Article Free upon publication Full Text Full Text (PDF) All Versions of this Article: 116/2/131    most recent CIRCULATIONAHA.107.712349v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Eikelboom, J. W. Articles by Weitz, J. I. Search for Related Content PubMed PubMed Citation Articles by Eikelboom, J. W. Articles by Weitz, J. I. Related Collections Deep vein thrombosis Coagulation inhibitors Other anticoagulants Anticoagulants

(Circulation. 2007;116:131-133.)
© 2007 American Heart Association, Inc.

Editorial

A Replacement for Warfarin

The Search Continues

From the Departments of Medicine (J.W.E., J.I.W.) and Biochemistry and Biomedical Sciences (J.I.W.), McMaster University and Henderson Research Centre, Hamilton, Ontario, Canada.

Correspondence to Dr Jeffrey Weitz, Henderson Research Centre, 711 Concession St, Hamilton, Ontario, L8V 1C3, Canada. E-mail jweitz@thrombosis.hhscr.org

Key Words: Editorials • anticoagulants • thrombosis

An extract of the first 250 words of the full text is provided, because this article has no abstract.

Vitamin K antagonists (VKAs) such as warfarin are the only oral anticoagulants currently available for clinical use. Warfarin has numerous limitations, including slow onset and offset of action, a narrow therapeutic window, and a metabolism that is affected by diet, drugs, and genetic polymorphisms.¹ Because of its unpredictable dose response, warfarin requires careful coagulation monitoring to ensure that a therapeutic anticoagulant effect is achieved.² Variable dose requirements, concern about the risk of bleeding, and the need for frequent coagulation monitoring have prompted the development of new oral anticoagulants to replace warfarin. With a predictable anticoagulant response and little potential for food or drug interactions, these new agents have been designed to be administered in fixed doses without coagulation monitoring. Consequently, these drugs have the potential to simplify long-term anticoagulant therapy.

Article p 180

The features of the new oral anticoagulants in the most advanced stages of clinical development are listed in the Table and are compared with those of warfarin. Unlike warfarin, which reduces the functional levels of factors II (prothrombin), VII, IX, and X, these novel agents are directed against the active site of factor Xa or thrombin, the enzymes responsible for thrombin generation and fibrin formation, respectively (see the Figure). Rivaroxaban and apixaban target factor Xa, whereas dabigatran etexilate inhibits thrombin.

View larger version (19K):   Targets of new oral anticoagulant drugs. Oral factor Xa inhibitors (rivaroxaban, apixaban) bind directly to factor Xa and prevent thrombin generation. Dabigatran etexilate, . . . [Full Text of this Article]

This article has been cited by other articles:

				L. G. Bucciarelli, A. Pollreisz, M. Kebschull, A. Ganda, A. Z. Kalea, B. I. Hudson, Y. S. Zou, E. Lalla, R. Ramasamy, P. C. Colombo, et al. Inflammatory stress in primary venous and aortic endothelial cells of type 1 diabetic mice Diabetes and Vascular Disease Research, October 1, 2009; 6(4): 249 - 261. [Abstract] [PDF]

				M. Boodhwani, P. Voisine, M. Ruel, N. R. Sodha, J. Feng, S.-H. Xu, C. Bianchi, and F. W. Sellke Comparison of vascular endothelial growth factor and fibroblast growth factor-2 in a swine model of endothelial dysfunction Eur. J. Cardiothorac. Surg., April 1, 2008; 33(4): 645 - 650. [Abstract] [Full Text] [PDF]

				M. P. Janjigian and B. E. Muhs Current Treatment of Acute Lower Extremity Deep Venous Thrombosis International Journal of Lower Extremity Wounds, March 1, 2008; 7(1): 15 - 20. [Abstract] [PDF]

				P. Herijgers and P. Verhamme Improving the quality of anticoagulant therapy in patients with mechanical heart valves: what are we waiting for? Eur. Heart J., October 2, 2007; 28(20): 2424 - 2426. [Full Text] [PDF]